Value Beacon
Long/short equity

A Short Case For PDL Biopharma: Why The Company Is Worth Less Than $5 A Share

A short case for PDL Biopharma: Simple math to understand why PDLI is worth less than $5 a share

In this note I will attempt to explain why I believe PDL Biopharma (NYSE: PDLI) may have substantial downside risk, why investors may be choosing to ignore this risk, why it only takes simple math to understand...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.